Clinical Trial Update: Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial is evaluating camrelizumab plus decitabine in patients with relapsed/refractory classical Hodgkin lymphoma who are PD-1 treatment-naive.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Decitabine (Decitabine)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hodgkin Lymphoma | Phase 2, Phase 3 | Status: UNKNOWN